These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 37702746

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy of Antiosteoporotic Medications in Patients With Rebound-Associated Fractures After Denosumab Discontinuation.
    Anastasilakis AD, Polyzos SA, Makras P, Trovas G, Yavropoulou MP, Tournis S.
    J Clin Densitom; 2021; 24(4):591-596. PubMed ID: 33541775
    [Abstract] [Full Text] [Related]

  • 3. Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study.
    Tutaworn T, Nieves JW, Wang Z, Levin JE, Yoo JE, Lane JM.
    Osteoporos Int; 2023 Mar; 34(3):573-584. PubMed ID: 36602607
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial.
    Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P.
    J Bone Miner Res; 2019 Dec; 34(12):2220-2228. PubMed ID: 31433518
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation.
    Anastasilakis AD, Polyzos SA, Yavropoulou MP, Appelman-Dijkstra NM, Ntenti C, Mandanas S, Papatheodorou A, Makras P.
    Calcif Tissue Int; 2021 May; 108(5):587-594. PubMed ID: 33386953
    [Abstract] [Full Text] [Related]

  • 8. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.
    Zanchetta MB, Boailchuk J, Massari F, Silveira F, Bogado C, Zanchetta JR.
    Osteoporos Int; 2018 Jan; 29(1):41-47. PubMed ID: 28975362
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis.
    Ebina K, Hashimoto J, Kashii M, Hirao M, Miyama A, Nakaya H, Tsuji S, Takahi K, Tsuboi H, Okamura G, Etani Y, Takami K, Yoshikawa H.
    Mod Rheumatol; 2021 Mar; 31(2):485-492. PubMed ID: 32412351
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than Single Infusion?
    Grassi G, Ghielmetti A, Zampogna M, Chiodini I, Arosio M, Mantovani G, Eller-Vainicher C.
    J Clin Endocrinol Metab; 2024 Sep 16; 109(10):e1817-e1826. PubMed ID: 38609157
    [Abstract] [Full Text] [Related]

  • 13. Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months.
    Anastasilakis AD, Polyzos SA, Makras P, Gkiomisi A, Bisbinas I, Katsarou A, Filippaios A, Mantzoros CS.
    Osteoporos Int; 2014 May 16; 25(5):1633-42. PubMed ID: 24599275
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The impact of switching once-weekly teriparatide to denosumab in osteoporosis patients.
    Miyagi M, Fujimaki H, Naruse K, Suto K, Inoue G, Nakazawa T, Imura T, Saito W, Uchida K, Shirasawa E, Takahira N, Takaso M.
    J Orthop Sci; 2019 Jan 16; 24(1):153-158. PubMed ID: 30146385
    [Abstract] [Full Text] [Related]

  • 16. Differential effects of teriparatide, denosumab and zoledronate on hip structural and mechanical parameters in osteoporosis; a real-life study.
    Jaarah N, Lam CFJ, Lodhia N, Dulnoan D, Moore AE, Hampson G.
    J Endocrinol Invest; 2024 Jul 16; 47(7):1667-1677. PubMed ID: 38191946
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The Effect of Teriparatide for the Treatment of Multiple Spontaneous Clinical Vertebral Fractures after Discontinuation of Denosumab in a Female Patient with Rheumatoid Arthritis: A Case Report.
    Mori Y, Izumiyama T, Mori N, Aizawa T.
    Tohoku J Exp Med; 2021 May 16; 254(1):57-61. PubMed ID: 34053968
    [Abstract] [Full Text] [Related]

  • 19. Romosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extension.
    Cosman F, Oates M, Betah D, Timoshanko J, Wang Z, Ferrari S, McClung MR.
    J Bone Miner Res; 2024 Sep 02; 39(9):1268-1277. PubMed ID: 39041711
    [Abstract] [Full Text] [Related]

  • 20. Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial.
    Leder BZ, Tsai JN, Neer RM, Uihlein AV, Wallace PM, Burnett-Bowie SA.
    J Clin Densitom; 2016 Sep 02; 19(3):346-51. PubMed ID: 26900146
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.